基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
乳腺癌患者：谁将从新辅助化疗中获益？
英文原题：Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
查看英文原题
Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
新辅助化疗（NACT）的提出旨在手术前缩小肿瘤或阻止癌细胞扩散。遗憾的是，并非所有乳腺癌患者都能从NACT中获益，因此，患者必须在开始治疗前权衡治疗的风险和获益。目前，预测NACT疗效的数据有限。分子检测，如Oncotype DX、MammaPrint和Curebest 95GC，已被开发用于帮助判断哪些乳腺癌患者将从治疗中获益。人类白细胞抗原-DR同种型、TIL（肿瘤浸润淋巴细胞）、Fizzy相关蛋白同源物水平升高以及肿瘤相关巨噬细胞水平降低的患者似乎从NACT中获益最多。
展开英文摘要原文
Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited.
Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT.
论文信息
- 作者
- Yao L、Jia G、Lu L、Ma W
- 第一作者单位
- Department of Breast and Thyroid Surgery, The First Affiliated Hospital, School of Medicine, Huzhou University, Huzhou 313000, China.China
- 通讯作者单位
- Sanford Stem Cell Clinical Center, Moores Cancer Center, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.United States
- 文献类型
- 综述
- 期刊
- Current oncology (Toronto, Ont.)2022 Jul 12
- 原文标识
- PubMed 35877249 · DOI 10.3390/curroncol29070389
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →